Randomized trial · people
ARA-290 eased neuropathic symptoms in sarcoidosis nerve fiber loss
Checked against the paper Randomized trialPublished by PepVault
The takeaway
This is a controlled human trial in which ARA-290 improved nerve symptoms and corneal nerve fiber density in sarcoidosis over 28 days.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2013
- Journal
- Mol Med
What they tested
The team tested whether daily ARA-290 could ease symptoms in people with sarcoidosis who have small nerve fiber loss and damage (SNFLD).
How the study was done
A blinded, randomized, placebo-controlled trial in patients with sarcoidosis and documented SNFLD. They got either ARA-290 or a placebo (a dummy shot) as a daily injection under the skin for 28 days.

What they found
Patients on ARA-290 had a significant improvement in neuropathic (nerve-related) symptoms they reported themselves, compared with placebo. ARA-290 was also linked to a significant rise in the density of small nerve fibers in the cornea, the clear front layer of the eye. Patients also showed changes in how their skin sensed temperature. They walked farther on the 6-minute walk test, a measure of exercise capacity.
What it doesn’t show
Treatment lasted only 28 days, so the trial doesn't show whether the changes last or hold up over a longer course. It studied only sarcoidosis-related nerve fiber loss. The authors' view that ARA-290 could change the course of the disease is a suggestion, not something this trial tested.
The paper
Dahan et al. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Mol Med. 2013.
The compound
More studies on ARA-290
- ARA-290: more corneal nerve fibers at 28 days in sarcoidosis, 4 mg armRandomized trial · people · 2017
- ARA-290 improved small fiber neuropathy symptoms in sarcoidosisRandomized trial · people · 2012
- ARA-290 eased nerve-injury pain for up to 20 weeks in ratsAnimal study · rats · 2014
- Every study on ARA-290
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.